p-thiomethylphenyl acetic acid | 1378851-95-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-thiomethylphenyl acetic acid
• 英文别名: 2-[4-(Sulfanylmethyl)phenyl]acetic acid
• CAS: 1378851-95-6
• 化学式: C₉H₁₀O₂S
• mdl: MFCD20659515
• 分子量: 182.243
• InChiKey: ITOZYMILMGZLBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  p-thiomethylphenyl acetic acid 在 氯化亚砜 作用下， 以 苯 为溶剂， 生成 p-thiomethylphenyl acetyl chloride
  参考文献：
  名称：

  Hypolipidemic allene carboxylic acids

  摘要：

  这些化合物是4-芳基取代的丁二烯酸及其酯，也可在2-和4-位置之一进行较低烷基取代，例如4-(对甲氧基苯基)-2-甲基丁二烯酸。这些化合物可作为药物使用，例如作为抗炎药和降脂药。

  公开号：

  US04011339A1

文献信息

• 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
  申请人：FAES FARMA, S.A.

  公开号：EP2135864A1

  公开（公告）日：2009-12-23

  The invention relates to the use of a compound of formula (I): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, in the preparation of a medicament for the treatment of an acute or chronic inflammatory disease, by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha and IFN-gamma, or by inmunomodulating the IL-8 chemokine and/or the IL-10 regulatory cytokine. The invention also relates to novel compounds of formula (I'): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, as well as a pharmaceutical composition comprising said compound.

  该发明涉及使用以下式（I）的化合物： 或其药学上可接受的盐、前药和/或溶剂化物，在制备用于治疗急性或慢性炎症性疾病的药物时，通过抑制至少选择自TNF-alpha和IFN-gamma的一种促炎细胞因子的产生，或通过免疫调节IL-8趋化因子和/或IL-10调节细胞因子。该发明还涉及以下式（I'）的新化合物： 或其药学上可接受的盐、前药和/或溶剂化物，以及包含该化合物的药物组合物。
• 5-(4-METHANESULFONYL-PHENYL)-THIAZOLE DERIVATIVES FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATORY DISEASES
  申请人：Rubio Royo Victor

  公开号：US20090312376A1

  公开（公告）日：2009-12-17

  The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and to a method for the treatment an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, which comprises administering to a patient who needs such treatment a therapeutically effective amount of a compound of formula (I) as defined above.

  该发明涉及一种化合物，其化学式为(I)： 或其药学上可接受的盐、前药和/或溶剂化合物，以及通过抑制至少一种从TNF-alpha、IFN-gamma、IL-8和IL-10中选择的促炎细胞因子的产生来治疗急性或慢性炎症性疾病的方法，包括向需要此类治疗的患者施用上述定义的化合物(I)的治疗有效量。
• Therapeutic isoquinoline compounds
  申请人：Haeberlein Markus

  公开号：US20070010526A1

  公开（公告）日：2007-01-11

  Provided herein is a compound of the formula (I), wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT 1B and 5HT 1D antagonists.

  本文提供了一种公式（I）的化合物，其中这些化合物可用于治疗精神障碍，包括但不限于抑郁症、广泛性焦虑症、进食障碍、痴呆症、恐慌症和睡眠障碍。这些化合物也可用于治疗胃肠道障碍、心血管调节、运动障碍、内分泌障碍、血管痉挛和性功能障碍。这些化合物是5HT1B和5HT1D拮抗剂。
• PHOTO-CURING MATERIAL MANUFACTURING METHOD, AND PHOTO-CURING MATERIAL AND ARTICLE
  申请人：Asahi Glass Company Limited

  公开号：EP2360195A1

  公开（公告）日：2011-08-24

  To provide a photocurable material which can form a cured product having a high transparency and a high refractive index, a process for producing the material easily, and an article having a high transparency and a high refractive index. The photocurable material is obtained by a production process comprising (i) a step of reacting a polymerizable component (A) comprised of at least one type of a compound (a) having a (meth)acryloyloxy group, and a compound (B) having a mercapto group and a carboxy group to obtain a surface modifier (C) which has the carboxy group derived from the compound (B) at a terminal, (ii) a step of modifying the surface of inorganic fine particles (D) with the surface modifier (C) to obtain surface-modified inorganic fine particles (E), and (iii) a step of obtaining a photocurable material which contains the surface-modified inorganic fine particles (E), a polymerizable component (F) comprised of at least one type of a compound (f) having a (meth)acryloyloxy group, and a photopolymerization initiator (G).

  提供一种可形成具有高透明度和高折射率的固化物的光固化材料、一种易于生产该材料的工艺以及一种具有高透明度和高折射率的制品。 这种光固化材料是通过以下生产工艺获得的： (i) 第一步：使由至少一种具有(甲基)丙烯酰氧基的化合物(a)和具有巯基和羧基的化合物(B)组成的可聚合组分(A)与表面改性剂(C)反应，表面改性剂(C)的末端具有来自化合物(B)的羧基、(ii) 用表面改性剂（C）改性无机微粒（D）的表面，以获得表面改性无机微粒 （E），以及 (iii) 获得光固化材料的步骤，该材料包含表面改性无机微粒（E）、由至少一种具有 （甲基）丙烯酰氧基的化合物（f）和光聚合引发剂（G）组成的可聚合组分（F）。
• THERAPEUTIC ISOQUINOLINE COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1451172A1

  公开（公告）日：2004-09-01